Hypersensitivity reactions to proton pump inhibitors. An <scp>EAACI</scp> position paper
Sevim Bavbek, Seçil Kepil Özdemir, Patrizia Bonadonna, Marina Atanasković‐Marković, A. Barbaud, Knut Brockow, José Julio Laguna, Alla Nakonechna, Mauro Pagani, Alessandra Arcolacı, Carla Lombardo, Marı́a José Torres
Abstract
Proton pump inhibitors (PPIs) are invaluable therapeutic options in a variety of dyspeptic diseases. In addition to their well-known risk profile, PPI consumption is related to food and environmental allergies, dysbiosis, osteoporosis, as well as immediate and delayed hypersensitivity reactions (HSRs). The latter, although a rare event, around 1%-3%, due to the extraordinarily high rate of prescription and consumption of PPIs are related to a substantial risk. In this Position Paper, we provide clinicians with practical evidence-based recommendations for the diagnosis and management of HSRs to PPIs. Furthermore, the unmet needs proposed in the document aim to stimulate more in-depth investigations in the topic.